57 CHEMICALS KNOWLEDGE HUB Issue 2 / October 2025 ROUNDTABLE clinical projects and large-scale commercial programs. That ability to pivot between scales ensures we support customers as their therapies progress and ultimately helps bring medicines to patients faster. However, patient-centricity isn’t only about timelines. It also means embedding responsibility and sustainability into how we operate. Our investment program goes hand-in-hand with local job creation, community engagement and greener manufacturing practices such as solvent reduction. Patients, regulators and society expect us to balance growth with responsibility. Above all, patient-centricity reinforces our mindset: start by asking what customers and their patients need, not by focusing solely on what we are already good at. That is the anchor of our business strategy. EK. The growing demand for patient-centric care is reshaping how therapies are developed and delivered, and nasal spray technology is naturally aligned with this shift. Patients want treatments that are less invasive, easier to administer and more compatible with their daily lives. Nasal sprays meet all three criteria. They are self-administered, needle free and do not require a healthcare provider. This supports greater independence and better dosing adherence, especially for chronic and long-term conditions. This is particularly important as we see nasal delivery expanding into new indications like acute rescue therapies, depression and even seizure management. Nasal sprays excel where fast, at-home administration is critical. At Renaissance Lakewood, we’re seeing increased demand from partners developing patient-ready nasal spray products that are shelf stable, portable and intuitive to use. As the healthcare landscape shifts toward at-home and self-care models, we believe nasal drug delivery will play a pivotal role in making advanced therapeutics more accessible and less burdensome to patients. The drug’s effectiveness depends not only on the API, but also on the patient’s correct usage. LS. The rise of biopharma and advanced therapies reinforces our commitment to strategic and proactive planning across our own operations. These therapies require different manufacturing conditions, higher levels of sterility assurance, and agile supply chains. We’re investing in specialised capabilities and looking closely at how we partner with clients to meet them and solve challenges at any stage in their development cycles by offering more integrated, end-to-end support. What impact is the rise of biopharma and advanced therapies having on your supply chain and manufacturing decisions? PV. Advanced therapies require more flexible, smaller-scale and highly specialised manufacturing capabilities. This is reshaping our supply chain, with greater emphasis on scalability, traceability and quality. We’re seeing a move toward decentralised and, in some cases, personalised production. That calls for close collaboration with specialised CDMOs, investments in singleuse technologies and digital twins, and building redundancy into supply networks to reduce risk. BC. The rise of biopharma is reshaping supply chain and manufacturing strategies across the industry. Unlike small molecules, biologics require highly specialised processes and infrastructure, pushing companies to build greater flexibility, resilience and technical expertise into their operations. At Mabion, this has meant investing in modular and platform-based biomanufacturing and bioprocessing capabilities. Developing adaptive facilities enables us to handle a diverse range of projects without compromising on quality or speed. The volatility of global supply chains makes diversification essential and supply chain resilience has become a critical factor. The Covid-19 pandemic exposed vulnerabilities in global sourcing of raw materials, consumables and critical components such as single-use systems. Building relationships with reliable CDMOs that implement redundancy in sourcing strategies ensures client needs are met even in times of disruption. Another key impact is the growing emphasis on GMP-grade materials and advanced analytics. Innovative therapies often require new assays, custom reagents and specialised cold-chain logistics. To address these evolving needs, we have expanded our quality systems and invested in strategic partnerships. MM. The rapid growth of advanced therapies is driving us to reimagine supply chains and manufacturing models. Customers need assurance that their therapies will be delivered on time, at scale and in compliance with evolving global regulations. At the same time, small molecules continue to account for the bulk of global demand and that dual reality drives our strategy. Our approach is threefold. First, we are investing across our manufacturing sites, increasing our
RkJQdWJsaXNoZXIy MjY2OTA4MA==